- Conditions
- Osteogenesis Imperfecta
- Interventions
- Bone Marrow Cell Transplantation, Irradiation, Total Body, Cyclophosphamide, Cyclosporin, Mesenchymal Stem Cell Transplantation, Busulfan
- Other · Radiation · Drug + 1 more
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 3 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1995 – 2007
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–10
of 10
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Osteogenesis Imperfecta Type II, Osteogenesis Imperfecta Type III
- Interventions
- Mesenchymal Stromal Cells
- Biological
- Lead sponsor
- Nationwide Children's Hospital
- Other
- Eligibility
- Up to 19 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Osteogenesis Imperfecta
- Interventions
- BPS804
- Drug
- Lead sponsor
- Ultragenyx Pharmaceutical Inc
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 2
- States / cities
- Albuquerque, New Mexico • Houston, Texas
- Conditions
- Osteogenesis Imperfecta
- Interventions
- Setrusumab
- Biological
- Lead sponsor
- Ultragenyx Pharmaceutical Inc
- Industry
- Eligibility
- 19 Years to 80 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Albuquerque, New Mexico
- Conditions
- Osteogenesis Imperfecta
- Interventions
- Zoledronic Acid
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 1 Year to 17 Years
- Enrollment
- 127 participants
- Timeline
- 2004 – 2007
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Wilmington, Delaware • Boise, Idaho + 7 more
- Conditions
- Osteogenesis Imperfecta
- Interventions
- Fresolimumab
- Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 2
- States / cities
- Portland, Oregon • Houston, Texas
- Conditions
- Osteogenesis Imperfecta
- Interventions
- Humatrope
- Drug
- Lead sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- NIH
- Eligibility
- 3 Years to 16 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1991 – 2017
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Osteogenesis Imperfecta, Type I, Osteogenesis Imperfecta Type III, Osteogenesis Imperfecta Type IV
- Interventions
- setrusumab, Calcium, Vitamin D, zoledronic acid (optional)
- Drug · Dietary Supplement
- Lead sponsor
- Ultragenyx Pharmaceutical Inc
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Jacksonville, Florida • Baltimore, Maryland + 9 more
- Conditions
- Osteogenesis Imperfecta
- Interventions
- Bisphosphonate, Setrusumab
- Drug · Biological
- Lead sponsor
- Ultragenyx Pharmaceutical Inc
- Industry
- Eligibility
- 2 Years to 6 Years
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 10 more
- Conditions
- Osteogenesis Imperfecta (OI)
- Interventions
- AGA2115, Placebo
- Drug · Other
- Lead sponsor
- Angitia Incorporated Limited
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 9
- States / cities
- Phoenix, Arizona • New Haven, Connecticut • Wilmington, Delaware + 6 more